Vall d'Hebron Institute of Oncology (VHIO)
Laura Soucek has a diverse and extensive work experience in the field of cancer research and molecular biology. Laura is currently a member of referentsfemenins.cat. Previously, they held positions at Vall d'Hebron Institute of Oncology (VHIO) as the Director of the Preclinical and Translational Research Program and as the Head of Models of Cancer Therapies Laboratory. Laura is also a Research Professor at ICREA. In addition, Laura Soucek is the Founder and Chief Executive Officer of Peptomyc, a company focused on developing cancer therapies. Laura has also served as an Associate Professor at Universitat Autònoma de Barcelona. Earlier in their career, they worked as a Research Assistant Molecular Biologist at UCSF, Comprehensive Cancer Center and as a Postdoc at UCSF. Laura also worked as a Molecular Biologist at Istituto di Biologia e Patologia Molecolari, Roma and as a PhD student (Genetics and Molecular Biology) at University La Sapienza, Roma, Italy.
Laura Soucek has a diverse education history. In 2020, they completed "The Pharma Business Development" course at CELforPharma, specializing in business development. In 2018, they also pursued an advanced business development course at EBD Academy. Earlier in their academic journey, they obtained a PhD in Genetics and Molecular Biology from Sapienza Università di Roma between 1997 and 2000. Prior to that, they earned their University Degree in Biology, with a specialization in Biotechnology, from the same institution between 1991 and 1996. Laura'seducational background began with a Maturita' Classica received from Liceo Classico A. Mancinelli in 1991. Additionally, they have taken "The Pharmaceutical Out-licensing Course" at CELforPharma, but the duration and specific field of study are not provided.
This person is not in any teams
Vall d'Hebron Institute of Oncology (VHIO)
Under the leadership of Josep Tabernero, the Vall d’Hebron Institute of Oncology (VHIO) has established itself as a cancer research center of proven excellence internationally. It is thanks to Josep's directorship and VHIO's optimal organizational structure based on a purely multidisciplinary and translational model that VHIO talents continue to anticipate and tackle the many unresolved questions in combatting this multifaceted and heterogeneous disease. Located within the Vall d´Hebron Barcelona Hospital Campus, our researchers closely collaborate and interact with Vall d´Hebron University Hospital physician-scientists. Translational science and clinical research are therefore tightly connected which promotes superb interaction and teamwork which, in turn, accelerates the bench-bedside-bed cycle of knowledge. This privileged environment affords VHIO direct access to patients as well as the entire spectrum of oncology professionals who care for them, and a second-to-none appreciation of how cancer science can translate into more powerful, targeted treatments and better practice for the care of patients. VHIO's pioneering model and programs, coupled with its belief in combining strengths through cross-border collaborations, continue to spur advances in reversing cancer resistance, halting metastatic spread and more effectively treating even the most undruggable tumour types. VHIO's translation toward precision oncology.